APA (7th ed.) Citation

H, Z., X, Z., C, W., G, W., Q, T., J, Z., . . . X, W. (2025). Combination therapy using Cel-CSO/Taxol NPs for reversing drug resistance in breast cancer through inhibiting PI3K/AKT/NF-κB/HIF-1α pathway. Drug delivery and translational research, 15(3), 992. https://doi.org/10.1007/s13346-024-01653-3

Chicago Style (17th ed.) Citation

H, Zeng, et al. "Combination Therapy Using Cel-CSO/Taxol NPs for Reversing Drug Resistance in Breast Cancer Through Inhibiting PI3K/AKT/NF-κB/HIF-1α Pathway." Drug Delivery and Translational Research 15, no. 3 (2025): 992. https://doi.org/10.1007/s13346-024-01653-3.

MLA (9th ed.) Citation

H, Zeng, et al. "Combination Therapy Using Cel-CSO/Taxol NPs for Reversing Drug Resistance in Breast Cancer Through Inhibiting PI3K/AKT/NF-κB/HIF-1α Pathway." Drug Delivery and Translational Research, vol. 15, no. 3, 2025, p. 992, https://doi.org/10.1007/s13346-024-01653-3.